S100A12在子痫前期患者母血中的表达及相关性研究

目的探讨S100A12在子痫前期患者母血清中的表达和临床意义。方法分别抽取24例子痫前期轻度患者、24例子痫前期重度患者以及24例正常妊娠妇女的血液,收集所有患者完整的病例资料,采用免疫印迹法检测血清中S100A12蛋白表达水平,并采双抗体夹心酶联免疫吸附法检测血清中TNF-α和IL-6的表达。结果与正常组相比,子痫前期患者血清中S100A12、IL-6和TNF-α的表达水平显著升高（P〈0.05）,且S100A12的表达水平与IL-6存在显著正相关性（P〈0.05）。结论 S100A12在子痫前期患者血清中的表达水平明显升高,有可能用于临床上子痫患者的诊断和治疗。

Expression of S100A12 in the maternal blood of patients with pre-eclampsia

Objective：To explore the relationship of S100A12 in the maternal blood of patients with pre-eclampsia and their roles on pathogenesis of pre-eclampsia.Methods：Western blot was used to investigate the expression level of S100A12 in the maternal blood of patients with pre-eclampsia including mild and moderate preeclampsia 24 cases,severe preeclampsia 24 cases and 24 cases normal pregnant women. Maternal and umbilical serum IL-6and TNF-alpha were calculated by using enzyme-linked immunosorbent assay.Results：Compared with the control group,the level of S100A12 protein in maternal blood of pre-eclampsia patients were significantly increased（P〈0.05）. Significantly increased maternal and umbilical serum levels of IL-6 and TNFalpha were found in patientswith pre-eclampsia group in comparison with the control group（P〈0.05）.There is a significant positive correlation between high expression of IL-6,TNF-α and S100A12 in pre-eclampsia（P〈0.05）.Conclusion：S100A12 plays an important role in the pathogenesis of pre-eclampsia and may be served as a therapeutic target for the treatment of pre-eclampsia.